How fast do you see results with Wegovy?

What happens in the first few weeks — is it normal for nothing to change on the scales?

Yes, and it is worth understanding why. Wegovy (semaglutide) starts at 0.25mg, a tolerability dose whose job is to let your body adjust rather than to produce rapid weight loss. At this early stage, many people notice they feel full sooner or simply less interested in snacking, but the scales may barely shift. That is expected, not a sign the medicine is not working.

By weeks four to eight, as the dose steps up to 0.5mg and then 1mg, a clearer downward trend tends to emerge. If you want a fuller picture of how soon you see results with Wegovy, including what to watch for at each stage, that page breaks it down week by week. Our prescribers hear this regularly: the early weeks feel slow, then progress becomes more consistent.

Gastrointestinal side effects (nausea, some queasiness, occasional loose stools) are most common during the first few weeks or after a dose increase, and they usually settle. The NHS semaglutide medicines page has a clear overview of what to expect and when to seek advice. Pushing through this early phase, with your prescriber's support, is what gets most people to the doses where meaningful weight loss occurs.

When do most people reach their biggest results, and what do the trial figures actually mean?

The headline figure comes from the STEP 1 trial: adults with obesity lost an average of around 15% of their body weight over 68 weeks at the 2.4mg maintenance dose. That is roughly 15kg for someone starting at 100kg. Published in the New England Journal of Medicine, the trial involved nearly 1,961 adults alongside a lifestyle programme, so diet and activity were part of the picture throughout.

Weight loss in those 68 weeks was not linear. The steepest drop typically occurred between weeks 16 and 36, once participants reached or approached the maintenance dose. Progress then slowed and plateaued, which is a normal biological response rather than a failure. If you are curious how the overall timeline from first dose to plateau maps out, that page goes into more detail.

The newer 7.2mg single-dose pen, approved by the MHRA in April 2026, shows around 20.7% average weight loss over 72 weeks, narrowing the gap with tirzepatide results. That is a separate titration pathway, confirmed at consultation. What matters practically is that the biggest results come after the full titration period, not in the first month.

Does how fast you lose weight depend on which dose you reach?

Significantly, yes. The 2.4mg maintenance dose in STEP 1 produced around 15% average loss; participants who did not tolerate the full titration and stayed on lower doses lost less on average. This is why the titration schedule matters, and why the decision to slow, hold or adjust a dose increase sits with your prescriber rather than with the patient alone.

For people considering the full Wegovy treatment overview, one practical note: the titration to 2.4mg typically takes about 16 to 20 weeks. Results at month one are not predictive of results at month six. A question our prescribers field most weeks is whether slow early progress means the medicine is not working, usually it does not. It means the dose is still climbing.

Lifestyle factors matter throughout. Protein intake, staying hydrated and some form of resistance activity all help preserve muscle as weight falls, which supports longer-term results. Nutrition guidance is worth discussing with your prescriber or a dietitian alongside treatment. For context on how long Wegovy takes to work across different starting points, that page covers the variables in more depth.

What if results slow down or stop, is that a reason to stop treatment?

A plateau is not automatically a reason to stop. Weight loss tends to slow once the body adjusts to a new set point, and this is true with or without medication. The clinical question is whether you have reached your highest tolerated dose and given it adequate time. Under NICE guidance TA875, prescribers are advised to review whether to continue if weight loss is less than 5% after six months at the maintenance dose, so there is a formal checkpoint built into proper clinical oversight.

At nume, every repeat order is clinically re-reviewed; a prescriber checks your progress before anything is dispensed. There are no auto-renewals. If results have stalled and there is a clinical conversation to be had, it happens before the next pen ships, not after. You can explore what results look like over time to get a more visual sense of typical trajectories, keeping in mind that individual variation is wide.

One useful comparison point: some people also want to know how soon weight loss specifically shows versus when appetite changes first, since those two things often happen at different points. If you are weighing up whether Wegovy or another licensed treatment suits your situation better, exploring the weight-loss treatment options available at nume is a sensible next step. When you are ready, you can speak to our prescribers through a free consultation, reviewed the same day by a GPhC-registered clinician, not a questionnaire bot.